V. Michael Holers, MD
Professor, Medicine-Rheumatology

Head, Division of Rheumatology
Smyth Professor of Rheumatology
Clinic 303-724-2323
Print Profile
Email Profile

Gender: Male
Languages: English
Department, Section/Division: Medicine-Rheumatology
Immunology and Microbiology

Practice Locations

Barbara Davis Center for Childhood Diabetes - Specialty Clinic
1775 Aurora Ct
Aurora, CO 80045
More providers at this location

Hospital Affiliation
  • University of Colorado Hospital

Specialty Information

  • Internal Medicine, Board Certification
  • Internal Medicine - Rheumatology, Board Certification

Information for Referring Providers

Clinical Interests for Referring Providers
I am interested in Complement and SLE, RA Pathogenesis.

Research Interest for Referring Providers
Dr. Holers is performing basic and translational research on the roles of complement receptors and membrane regulatory proteins in the immune response, with a special emphasis on B lymphocytes and autoimmune diseases. Complement is a complex system of serum proteins which, upon activation, covalently bind targets (bacteria, viruses, immune complexes) and marks them as foreign. The interaction of complement with B cell receptors also results in substantial enhancement of humoral and cellular immunity. In addition to this role, excessive activation of complement is centrally involved in autoimmunity and the tissue damage that occurs in many inflammatory diseases involving organs such as the kidney. The Holers’ laboratory has developed human and mouse models in which to study these complement related biologic processes and develop inhibitors. With regard to the natural history studies of RA, we now know that autoimmune diseases begin years before clinical signs and symptoms are apparent, when at-risk individuals manifest highly predictive autoantibodies in their serum. This observation suggests that additional therapeutic and/or prevention strategies could be considered for individuals in this at-risk but asymptomatic period. It is also relevant to determine how individuals transition from this autoantibody-positive, at-risk period to clinically active disease, and ongoing studies have been started that are related to understanding these questions.

Contact Us
In An Emergency: Please Dial 911

University of Colorado Medicine (CU Medicine)
Refer a Patient: 720-848-2828
Billing Questions: 303-493-7000

Twitter   Facebook
CU Doctors